Medigen Vaccine Biologics Corp.

Medigen Vaccine Biologics Corp.

TTPEX:6547
45.00
TWD
-0.75
(-1.64%)
-0.51EPS
14.94BMarket Cap
Mar 12Next Earn

Total Valuation

TWD

As of June 30, 2026, Medigen Vaccine Biologics Corp. carries a market capitalization of 14.94B, placing it among publicly traded companies globally. Its enterprise value stands at 14.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.94B
Enterprise Value14.00B

Important Dates

Medigen Vaccine Biologics Corp.'s next confirmed earnings release is scheduled for March 12, 2027.

Earnings Date3/12/2027

Share Statistics

As of June 30, 2026, Medigen Vaccine Biologics Corp. has 328.75M shares outstanding.

Shares Outstanding328.75M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 25.73, and the price-to-book ratio stands at 4.20.

PS Ratio25.73
PB Ratio4.20
P/TBV Ratio4.22
P/FCF Ratio-67.88
P/OCF Ratio-266.82

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 24.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 14.00B versus a market cap of 14.94B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales24.40

Financial Position

As of June 30, 2026, Medigen Vaccine Biologics Corp. maintains a current ratio of 22.37, meaning it holds 22.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 31.04, indicating elevated leverage, while an interest coverage ratio of -2.47 demonstrates limited ability to service its debt obligations.

Current Ratio22.37
Quick Ratio16.33
Debt / Equity31.04
Debt / EBITDA-32.86
Interest Coverage-2.47

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Medigen Vaccine Biologics Corp. posted a negative return on equity (ROE) of -4.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.75, reflecting losses generated across the asset base. The company generates approximately 4.28M in revenue per employee across its workforce of 134.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.41 indicates how many times Medigen Vaccine Biologics Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-4.62
Return on Assets (ROA)-3.75
Revenue Per Employee4.28M
Employee Count134.00
Inventory Turnover0.41

Stock Price Statistics

TWD

As of the close on November 17, 2026, Medigen Vaccine Biologics Corp.'s stock has gained approximately 21.13% over the past 52 weeks. The 50-day moving average sits at 55.46, while the 200-day moving average is 48.92.

52-Week Price Change21.13%
50-Day Moving Average55.46
200-Day Moving Average48.92

Income Statement

TWD

Over the twelve months ended June 30, 2026, Medigen Vaccine Biologics Corp. generated 573.85M in revenue and converted that into -166.77M in net income, yielding earnings per share of -0.51. EBITDA reached -33.59M, while operating income came in at -181.12M.

Revenue573.85M
Gross Profit361.55M
Operating Income-181.12M
Pretax Income-166.77M
Net Income-166.77M
EBITDA-33.59M
EBIT-181.12M
Earnings Per Share (EPS)-0.51

Balance Sheet

TWD

As of June 30, 2026, Medigen Vaccine Biologics Corp. holds 2.04B in cash and equivalents against 1.10B in total debt, resulting in a net debt position of 446.99M. Total book value stands at 3.56B, with working capital of 2.67B providing operational flexibility.

Cash & Cash Equivalents2.04B
Total Debt1.10B
Net Debt446.99M
Equity (Book Value)3.56B
Book Value Per Share10.81
Working Capital2.67B

Cash Flow

TWD

Medigen Vaccine Biologics Corp. produced -55.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -162.21M in capital expenditures, free cash flow totaled -217.55M - equivalent to -0.67 per share.

Operating Cash Flow-55.34M
Capital Expenditures-162.21M
Free Cash Flow-217.55M
FCF Per Share-0.67

Margins

Over the twelve months ended June 30, 2026, Medigen Vaccine Biologics Corp. posted a gross margin of 63.00, reflecting its pricing power and cost economics. The operating margin of -31.56 and net profit margin of -29.06 provide insight into operational efficiency.

Gross Margin63.00
Operating Margin-31.56
Pretax Margin-29.06
Profit Margin-29.06
EBITDA Margin-5.85

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.14, meaning Medigen Vaccine Biologics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-5.14
FCF Yield-1.47

Stock Splits

Medigen Vaccine Biologics Corp.'s most recent stock split took place on August 3, 2022 with a 727:1078 split ratio.

Last Split Date8/3/2022
Split Ratio727:1078

Scores

As of June 30, 2026, Medigen Vaccine Biologics Corp. has an Altman Z-Score of 8.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.11